The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

Hoth Therapeutics (HOTH) has been granted a key patent by the Japan Patent Office, expanding its global intellectual property portfolio in ...

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting ...

Getting therapeutic drugs past the blood-brain barrier has long been a major challenge in treating brain diseases. Now, researchers from Japan have explored how cholesterol-modified heteroduplex ...

This pathway, or others like it, could explain why some inheritable traits between generations can’t be explained exclusively via DNA and RNA. "There are a lot of traits and disorders that we ...

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $45 price target Ionis is a commercial-stage biotech ...

“The discovery of messenger RNA originated with the work of ORNL biologists and chemists in the 1950s, using techniques developed during our work on the Manhattan Project,” said Paul Langan, associate ...

BIIB080 is an investigational antisense oligonucleotide therapy that targets microtubule-associated protein tau mRNA preventing the production of the disease-causing protein. The Fast Track ...

BIIB080, an investigational antisense therapy, is a differentiated approach to targeting tau, with promising potential for patients. We are advancing this program with urgency on behalf of people ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 million series B fundraise. The round was led by Venrock Healthcare ...